ArticleMolecular pharmacology2012

Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.

Wenchang Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.